Outlook Therapeutics (Outlook Therapeutics) Total Assets : $21.69 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Outlook Therapeutics Total Assets?

Outlook Therapeutics's Total Assets for the quarter that ended in Dec. 2023 was $21.69 Mil.

During the past 12 months, Outlook Therapeutics's average Total Assets Growth Rate was 9.50% per year. During the past 3 years, the average Total Assets Growth Rate was 7.40% per year. During the past 5 years, the average Total Assets Growth Rate was -9.40% per year.

During the past 10 years, Outlook Therapeutics's highest 3-Year average Total Assets Growth Rate was 7.40%. The lowest was -26.60%. And the median was -12.20%.

Total Assets is connected with ROA %. Outlook Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 was -165.64%. Total Assets is also linked to Revenue through Asset Turnover. Outlook Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 was 0.00.

Outlook Therapeutics Total Assets Historical Data

The historical data trend for Outlook Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Total Assets Chart

Outlook Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Assets

Get a 7-Day Free Trial

17.14

19.73

22.81

28.53

32.30

Outlook Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Assets	Get a 7-Day Free Trial															62.69	54.02	44.45	32.30	21.69

Outlook Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Outlook Therapeutics's Total Assets for the fiscal year that ended in Sep. 2023 is calculated as

Total Assets	=	Total Equity (A: Sep. 2023 )	+	Total Liabilities (A: Sep. 2023 )
	=	-14.438	+	46.738
	=	32.30

Outlook Therapeutics's Total Assets for the quarter that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2023 )	+	Total Liabilities (Q: Dec. 2023 )
	=	-24.343	+	46.028
	=	21.69

Outlook Therapeutics (NAS:OTLK) Total Assets Explanation

Total Assets is connected with ROA %.

Outlook Therapeutics's annualized ROA % for the quarter that ended in Dec. 2023 is

ROA %	=	Net Income (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	-44.712	/	( (32.301	+	21.685)	/ 2 )
	=	-44.712	/	26.993
	=	-165.64 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Outlook Therapeutics's Asset Turnover for the quarter that ended in Dec. 2023 is

	Asset Turnover
=	Revenue (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
=	0	/	( (32.301	+	21.685)	/ 2 )
=	0	/	26.993
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Outlook Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics (Outlook Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (NAS:OTLK) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

41ON:Germany 41ON:Germany

Address

485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Executives

Terry Dagnon	officer: Chief Operating Officer	C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Jeff Evanson	officer: Chief Commercial Officer	C/O ONCOBIOLOGICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Yezan Munther Haddadin	director	ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA, 4TH FLOOR, PO BOX 142904, AMMAN M2 11844
Faisal Ghiath Sukhtian	director	7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BLDG,4TH FLR, PO BOX 142909, AMMAN M2 11844
Kurt J Hilzinger	director	1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Julia A Haller	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Trenary C Russell Iii	director, officer: CEO and President	1700 E ST ANDREW PLACE, SANTA ANA CA 92705
Ghiath M. Sukhtian	director, 10 percent owner	7TH CIRCLE, ZAHRAN ST., ZAHRAN PLAZA BUILDING, 4TH FLOOR, AMMAN M2 11844
Lawrence A Kenyon	officer: CFO and Secretary	C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE, CRANBURY NJ 08512
Syntone Ventures Llc	10 percent owner	1517 CHAMPLAIN CREST WAY, CARY NC 27513
Randy H Thurman	director	222 MERCHANDISE MART PLAZA, SUITE 2024, CHICAGO IL 60654
Andong Huang	director	C/O OUTLOOK THERAPEUTICS, INC., 4260 US ROUTE 1, MONMOUTH JUNCTION NJ 08852
Gerd Auffarth	director	C/O PRESBIA PLC, 120/121 BAGGOT STREET LOWER, DUBLIN 2 L2 00000
Julian S Gangolli	director	4955 BASELINE AVENUE, SANTA YNEZ CA 93460
Gms Ventures & Investments	director	C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD., 190 ELGIN AVENUE, GEORGE TOWN E9 KYI-9007